23.05.2016 • NewsElaine BurridgeClariantGevo

Clariant Develops Catalysts for Gevo Process

Swiss specialty chemicals company Clariant is to develop and scale up catalysts for Gevo’s ethanol-to-olefins (ETO) process technology. The single-step process uses Gevo’s proprietary mixed metal oxide catalysts to produce tailored mixes of polymer-grade propylene, high-purity isobutylene and hydrogen from fuel-grade ethanol.

Gevo said once the ETO technology has been successfully developed and scaled up, Clariant will be able to produce the quantities of catalyst needed to meet commercial production requirements. It added that while Clariant works on developing the catalyst, Gevo will focus most of its resources on the ongoing optimization of its core isobutanol technology.

ETO technology, said Gevo, has the potential to provide the ethanol industry, estimated at 25 billion gallons globally, a much broader set of end-product markets and margin opportunities beyond its use as a gasoline blendstock.

“We see the potential with this technology to address several major opportunities cutting across chemicals, plastics, fuels and hydrogen, said Gevo’s CEO Patrick Guber. Gevo has filed a series of patent applications relating to the technology and anticipates growing its ETO business through licensing.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.